Alzamend Neuro, Inc. (ALZN): who owns it and who trades it
As of Nov 16, 2026, ALZN insiders reported 3 open-market sales worth $14K and 2 purchases worth $110K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was William B. Horne (Director), with $7.1K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Alzamend Neuro
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, ALZN insiders reported $110K of open-market purchases and $14K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | Milton C Ault III | Director | Sale | 2,000 | $1.56 | $3.1K | Form 4 |
| Apr 14, 2026 | Milton C Ault III | Director | Purchase | 2,000 | $1.03 | $2.1K | Form 4 |
| Apr 14, 2026 | Milton C Ault III | Director | Purchase | 108,388 | $1.00 | $108K | Form 4 |
| Dec 23, 2025 | Milton C Ault III | Director | Sale | 1,851 | $2.07 | $3.8K | Form 4 |
| Dec 19, 2025 | William B. Horne | Director | Sale | 3,333 | $2.12 | $7.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Milton C Ault III | Director | $110K | $7K | Aug 26, 2026 |
| William B. Horne | Director | – | $7.1K | Dec 19, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ALZN short interest
Low short interest. 0.4% of ALZN shares are sold short: about 1 share in 275. Over the last 12 reports the number of shares short went down 91%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17,574 ALZN shares were sold short, 0.4% of the shares outstanding, down 48.6% from the report before. At the average daily volume of 16,714 shares, buying them all back would take about 1.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17,574 | 0.36% | -49% | 16,714 | 1.1 |
| Oct 15, 2026 | 34,177 | 0.71% | -69% | 49,912 | 1.0 |
| Sep 30, 2026 | 111,547 | 2.31% | -9% | 101,975 | 1.1 |
| Sep 15, 2026 | 123,017 | 2.55% | -22% | 107,555 | 1.1 |
| Aug 31, 2026 | 158,044 | 3.30% | -10% | 152,042 | 1.0 |
| Aug 14, 2026 | 176,570 | 3.69% | -25% | 47,300 | 3.7 |
| Jul 31, 2026 | 236,376 | 4.93% | -28% | 49,306 | 4.8 |
| Jul 15, 2026 | 328,289 | 8.63% | +108% | 314,073 | 1.1 |
| Jun 30, 2026 | 157,517 | 4.14% | +26% | 335,814 | 1.0 |
| Jun 15, 2026 | 125,367 | 3.30% | -16% | 53,248 | 2.4 |
| May 29, 2026 | 149,007 | 3.92% | -25% | 91,969 | 1.6 |
| May 15, 2026 | 199,574 | 5.25% | -3% | 37,416 | 5.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Alzamend Neuro company events
Alzamend Neuro filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (listing). The latest was on Nov 10, 2026.
- Nov 10, 2026AgreementAmended an earlier report. As disclosed in the Original Form 8-K, the Company entered into the Original Agreement with the Purchaser, pursuant to which the Company agreed to sell to the Purchaser up to 25,000 shares of the Company’s then newly designated Series D convertible preferred stock. Filing
- Sep 29, 2026AnnouncementShared information with investors. Filing
- Aug 3, 2026ListingThe Company notified Nasdaq that it was not in compliance with the majority independent board standard under Nasdaq Listing Rule 5605(b)(1) which requires listed companies to have a majority of the board of directors be comprised of “Independent Directors” (as defined in Nasdaq Listing Rule… Filing
- Jul 21, 2026AnnouncementAlzamend Neuro, Inc., a Delaware corporation has learned that Lynne Fahey McGrath, M.P.H., Ph.D., a director of the Company, passed away on July 20, 2026. Filing
- Apr 17, 2026VoteReported shareholder vote results. Filing
- Mar 20, 2026ListingAlzamend Neuro, Inc., a Delaware corporation received a letter from the Listing Qualifications staff of the Nasdaq Stock Market LLC indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026, did not satisfy the… Filing
- Mar 6, 2026AgreementAlzamend Neuro, Inc. entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, as sales agent to sell shares of its common stock, par value $0.0001, having an aggregate offering price of up to $3.0 million from time to time, through an “at the market offering” as… Filing
- Nov 18, 2025AnnouncementAlzamend Neuro, Inc., a Delaware corporation has learned that Andrew H. Woo, M.D., Ph.D., a director of the Company, passed away on November 14, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Alzamend Neuro financials
Famous investors that hold ALZN
1 of the 50 well-known investors we track reported holding ALZN in their latest 13F filing. The largest position is Ken Griffin's, worth $137K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 79,218 | $137K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Alzamend Neuro, Inc. (ALZN) stock
Are ALZN insiders buying or selling?
In the last 12 months, ALZN insiders reported 2 open-market purchases worth $110K and 3 sales worth $14K. The latest trade was on Aug 26, 2026. See every trade.
What is the short interest in ALZN?
As of Oct 30, 2026, 17,574 ALZN shares were sold short, 0.4% of the shares outstanding, down 48.6% from the report before. At the average daily volume of 16,714 shares, buying them all back would take about 1.1 trading days (days to cover). See the history.
Which famous investors hold ALZN?
1 of the 50 well-known investors we track reported ALZN in their latest 13F filing, including Ken Griffin. The largest position is worth $137K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.